text
stringlengths 1
711
|
|---|
0.6%
|
0.0%
|
0.5%
|
1.0%
|
1.5%
|
2.0%
|
2.5%
|
3.0%
|
3.5%
|
4.0%
|
4.5%
|
5.0%
|
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
|
Vicks Halls Mucinex Ricola
|
Strepsils Sudafed Robitussin Benylin
|
Source: Euromonitor, J.P. Morgan
|
As per NielsenIQ, KVUE lost -133 bps of value share in the four-week period ending
|
5/6/23, sequentially worse from losing -113 bps as of PYE while gaining +159 bps as of
|
PY. As it relates to volume share, the company seems to have improved YTD,
|
although it lost -3 bps in the four-week period ending 5/6/23 vs. -13 bps PYE but
|
slightly gained +6 bps as of PY. Below we show how both value and volume share
|
performed for the 4, 13, and 52 weeks ending 5/6/23 for KVUE and some of its
|
competitors.
|
Figure 102: Cough & Cold - U.S. Value Share
|
For Periods Ending 5/06/23, YOY (bps)
|
(133)
|
(230)
|
(156) (148)
|
(940)
|
(94) (93)
|
(6)
|
782
|
184
|
419
|
12 36
|
198
|
32
|
813
|
343
|
539
|
401
|
14
|
278
|
(1,200)
|
(1,000)
|
(800)
|
(600)
|
(400)
|
(200)
|
-
|
200
|
400
|
600
|
800
|
1,000
|
KENVUE PROCTER &
|
GAMBLE
|
BAYER AG RECKITT PRIVATE
|
LABEL
|
CHURCH &
|
DWIGHT
|
HALEON
|
4W 13W 52W
|
Source: NielsenIQ, J.P. Morgan
|
Figure 103: Cough & Cold - U.S. Volume Share
|
For Periods Ending 5/06/23, YOY (bps)
|
(3)
|
8
|
(2)
|
(0)
|
(22)
|
(1) (3)
|
(0)
|
28
|
5
|
9
|
6
|
1 2
|
(1)
|
25
|
7
|
9
|
17
|
0
|
3
|
(30)
|
(20)
|
(10)
|
-
|
10
|
20
|
30
|
40
|
KENVUE PROCTER &
|
GAMBLE
|
BAYER AG RECKITT PRIVATE
|
LABEL
|
CHURCH &
|
DWIGHT
|
HALEON
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.